ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Former Merck & Co. scientist Yang Xie has agreed to pay the U.S. Securities & Exchange Commission a penalty for insider trading related to Merck’s 2015 acquisition of Cubist Pharmaceuticals. Xie, at the time Merck’s director of global health outcomes research, bought shares in Cubist soon after learning that Merck would likely make an offer to acquire the biotech firm. He later sold them at a $2,287 profit, violating both Merck policy and insider trading law. Xie’s fine was $6,681, three times his profit on the trade.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X